Black Diamond Therapeutics Reports Positive Clinical Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2026
0mins
Source: NASDAQ.COM
- Clinical Trial Results: Black Diamond Therapeutics announced a median Progression-free Survival (mPFS) of 15.2 months from its Phase 2 trial of Silevertinib in non-small cell lung cancer patients with EGFR non-classical mutations, indicating the drug's potential, although the stock fell 6.20% to $3.33, reflecting investor caution about future prospects.
- Patient Response: Among 43 patients treated with 200 mg of Silevertinib once daily, over 53% remained on treatment, with the longest duration reaching 23.5 months, suggesting the drug's tolerability and efficacy, which may lay a foundation for the company's future market performance.
- Safety Analysis: No new safety signals were observed, and the rate of Treatment-Related Adverse Events (TRAEs) decreased to 28% following dose reduction, indicating improved patient safety while maintaining clinical responses, potentially boosting investor confidence in the drug.
- Future Development Plans: The company also plans to initiate a randomized Phase 2 trial of Silevertinib in newly diagnosed EGFRvIII-positive glioblastoma patients in May 2026, further expanding the drug's indications and demonstrating its strategic positioning in oncology treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDTX
Wall Street analysts forecast BDTX stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.250
Low
8.00
Averages
9.00
High
10.00
Current: 2.250
Low
8.00
Averages
9.00
High
10.00
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
See More
Black Diamond Therapeutics Reports Positive Clinical Results
- Clinical Trial Results: Black Diamond Therapeutics announced a median Progression-free Survival (mPFS) of 15.2 months from its Phase 2 trial of Silevertinib in non-small cell lung cancer patients with EGFR non-classical mutations, indicating the drug's potential, although the stock fell 6.20% to $3.33, reflecting investor caution about future prospects.
- Patient Response: Among 43 patients treated with 200 mg of Silevertinib once daily, over 53% remained on treatment, with the longest duration reaching 23.5 months, suggesting the drug's tolerability and efficacy, which may lay a foundation for the company's future market performance.
- Safety Analysis: No new safety signals were observed, and the rate of Treatment-Related Adverse Events (TRAEs) decreased to 28% following dose reduction, indicating improved patient safety while maintaining clinical responses, potentially boosting investor confidence in the drug.
- Future Development Plans: The company also plans to initiate a randomized Phase 2 trial of Silevertinib in newly diagnosed EGFRvIII-positive glioblastoma patients in May 2026, further expanding the drug's indications and demonstrating its strategic positioning in oncology treatment.
See More
Black Diamond Therapeutics Reports Positive Phase 2 Trial Results for Silevertinib
- Clinical Trial Results: Black Diamond Therapeutics announced that its Phase 2 trial of silevertinib for non-small cell lung cancer (NSCLC) patients showed a preliminary median progression-free survival (mPFS) of 15.2 months, significantly exceeding historical data for existing therapies, indicating the drug's potential as a transformative treatment.
- CNS Activity: Among 43 participants, 86% achieved objective responses in the central nervous system (CNS), with no patients developing de novo brain metastases, demonstrating silevertinib's effectiveness in preventing brain metastasis and potentially improving patient prognosis.
- Safety Analysis: Following dose reduction, the rate of treatment-related adverse events (TRAEs) greater than grade 3 decreased to 28%, and patients maintained or deepened clinical responses after dose adjustments, supporting a 150 mg once-daily dosing for pivotal development.
- Future Outlook: Black Diamond plans to meet with the FDA in 2026 to discuss its pivotal development plan, further advancing the clinical application of silevertinib to address the unmet medical needs of patients with EGFR non-classical mutations.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Biotech Stocks Surge Significantly
- MetaVia Stock Surge: MetaVia Inc. (MTVA) shares soared over 69% to $1.88 yesterday, driven by promising safety and tolerability results from its lead drug candidate DA-1726, with data expected in Q4 2026, potentially enhancing the company's market position in cardiometabolic diseases.
- Co-Diagnostics Benefits from Ebola Outbreak: Co-Diagnostics Inc. (CODX) saw its stock rise over 43% to $1.97, following the completion of assay development for the Bundibugyo virus amid an Ebola outbreak in the DRC and Uganda, likely increasing demand and revenue in the molecular diagnostics market.
- Edesa to Present New Data: Edesa Biotech Inc. (EDSA) shares jumped over 33% to $11.95, as the company prepares to present new data on Paridiprubart for acute kidney injury at the 2026 ERA Congress, potentially solidifying its innovative position in treating immune-related diseases.
- Adial Drug Development Progress: Adial Pharmaceuticals Inc. (ADIL) stock rose nearly 28% to $2.06, as its drug AD04 for Alcohol Use Disorder is set to enter a new Phase 3 trial, with earlier results showing promising efficacy in heavy drinkers, potentially opening new market opportunities for the company.
See More
Black Diamond Therapeutics Q1 Earnings Beat Expectations
- Earnings Beat: Black Diamond Therapeutics reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in the red.
- Sufficient Cash Reserves: As of March 31, 2026, the company holds $118.3 million in cash, cash equivalents, and investments, which is expected to fund operations into the second half of 2028, bolstering investor confidence in its operational sustainability.
- Market Reaction Tepid: Despite the earnings report slightly exceeding expectations, the market's muted response towards Black Diamond Therapeutics suggests a cautious investor sentiment regarding the company's future growth potential, which may impact stock performance.
- Historical Financial Data: The historical earnings data shows a GAAP EPS of -$0.27 that missed expectations, highlighting ongoing challenges in profitability and the need for the company to implement measures to improve its financial health.
See More
Black Diamond Therapeutics Shares Plunge 35.8% Amid Mixed Phase II Results
- Clinical Trial Results: Black Diamond Therapeutics reported a preliminary median progression-free survival (mPFS) of 15.2 months for its phase II trial of silevertinib in NSCLC patients with EGFR non-classical mutations, yet the stock plummeted 35.8% as investors expressed concerns over the early nature of the data and modest patient count.
- Patient Data Analysis: The study enrolled 43 patients treated with a 200 mg dose of silevertinib, with 53% remaining on therapy at the data cutoff, and the longest treatment duration reaching 23.5 months, indicating potential durability of responses, although longer follow-up is needed to clarify the final benefit-risk profile.
- CNS Activity: Silevertinib demonstrated an 86% objective response rate in the central nervous system (CNS), with no new brain metastases reported by the cutoff date, suggesting this profile could be pivotal for the company's development and regulatory strategy, particularly if maintained in larger datasets.
- Safety Management: No new safety signals were observed, but severe treatment-related adverse events decreased to 28% after dose reduction, supporting the decision to adjust the dose to 150 mg; however, the need for dose optimization may have contributed to the negative market reaction.
See More
Black Diamond Therapeutics Reports Positive Clinical Results
- Clinical Trial Results: Black Diamond Therapeutics announced a median Progression-free Survival (mPFS) of 15.2 months from its Phase 2 trial of Silevertinib in non-small cell lung cancer patients with EGFR non-classical mutations, indicating the drug's potential, although the stock fell 6.20% to $3.33, reflecting investor caution about future prospects.
- Patient Response: Among 43 patients treated with 200 mg of Silevertinib once daily, over 53% remained on treatment, with the longest duration reaching 23.5 months, suggesting the drug's tolerability and efficacy, which may lay a foundation for the company's future market performance.
- Safety Analysis: No new safety signals were observed, and the rate of Treatment-Related Adverse Events (TRAEs) decreased to 28% following dose reduction, indicating improved patient safety while maintaining clinical responses, potentially boosting investor confidence in the drug.
- Future Development Plans: The company also plans to initiate a randomized Phase 2 trial of Silevertinib in newly diagnosed EGFRvIII-positive glioblastoma patients in May 2026, further expanding the drug's indications and demonstrating its strategic positioning in oncology treatment.
See More
Black Diamond Therapeutics Reports Positive Phase 2 Trial Results for Silevertinib
- Clinical Trial Results: Black Diamond Therapeutics announced that its Phase 2 trial of silevertinib for non-small cell lung cancer (NSCLC) patients showed a preliminary median progression-free survival (mPFS) of 15.2 months, significantly exceeding historical data for existing therapies, indicating the drug's potential as a transformative treatment.
- CNS Activity: Among 43 participants, 86% achieved objective responses in the central nervous system (CNS), with no patients developing de novo brain metastases, demonstrating silevertinib's effectiveness in preventing brain metastasis and potentially improving patient prognosis.
- Safety Analysis: Following dose reduction, the rate of treatment-related adverse events (TRAEs) greater than grade 3 decreased to 28%, and patients maintained or deepened clinical responses after dose adjustments, supporting a 150 mg once-daily dosing for pivotal development.
- Future Outlook: Black Diamond plans to meet with the FDA in 2026 to discuss its pivotal development plan, further advancing the clinical application of silevertinib to address the unmet medical needs of patients with EGFR non-classical mutations.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Biotech Stocks Surge Significantly
- MetaVia Stock Surge: MetaVia Inc. (MTVA) shares soared over 69% to $1.88 yesterday, driven by promising safety and tolerability results from its lead drug candidate DA-1726, with data expected in Q4 2026, potentially enhancing the company's market position in cardiometabolic diseases.
- Co-Diagnostics Benefits from Ebola Outbreak: Co-Diagnostics Inc. (CODX) saw its stock rise over 43% to $1.97, following the completion of assay development for the Bundibugyo virus amid an Ebola outbreak in the DRC and Uganda, likely increasing demand and revenue in the molecular diagnostics market.
- Edesa to Present New Data: Edesa Biotech Inc. (EDSA) shares jumped over 33% to $11.95, as the company prepares to present new data on Paridiprubart for acute kidney injury at the 2026 ERA Congress, potentially solidifying its innovative position in treating immune-related diseases.
- Adial Drug Development Progress: Adial Pharmaceuticals Inc. (ADIL) stock rose nearly 28% to $2.06, as its drug AD04 for Alcohol Use Disorder is set to enter a new Phase 3 trial, with earlier results showing promising efficacy in heavy drinkers, potentially opening new market opportunities for the company.
See More
Black Diamond Therapeutics Q1 Earnings Beat Expectations
- Earnings Beat: Black Diamond Therapeutics reported a Q1 GAAP EPS of -$0.16, beating expectations by $0.02, indicating a slight improvement in financial performance despite remaining in the red.
- Sufficient Cash Reserves: As of March 31, 2026, the company holds $118.3 million in cash, cash equivalents, and investments, which is expected to fund operations into the second half of 2028, bolstering investor confidence in its operational sustainability.
- Market Reaction Tepid: Despite the earnings report slightly exceeding expectations, the market's muted response towards Black Diamond Therapeutics suggests a cautious investor sentiment regarding the company's future growth potential, which may impact stock performance.
- Historical Financial Data: The historical earnings data shows a GAAP EPS of -$0.27 that missed expectations, highlighting ongoing challenges in profitability and the need for the company to implement measures to improve its financial health.
See More
